Literature DB >> 27796257

Estimating 10-year cardiovascular disease risk in Asian patients with schizophrenia.

Gurpreet Rekhi1, Toe Toe Khyne2, Jimmy Lee3.   

Abstract

OBJECTIVE: This study aims to describe the cardiovascular risk profile of Asian patients with schizophrenia.
METHODS: Data was extracted from the databases of 139 patients with schizophrenia and 206 controls from two previous studies conducted at the Institute for Mental Health (IMH), Singapore. Their medical and smoking histories were obtained, and anthropometric parameters measured. Framingham risk score (FRS) calculator using body mass index was used to compute the 10-year cardiovascular disease risk (FRSBMI) and the vascular age (VABMI) for each participant. Data on fasting lipids were available for 80 patients and all the controls; hence the FRS for lipids (FRSlipids) and VA (VAlipids) were also computed. The difference between VA and actual age was computed as VAdiff.
RESULTS: The 10-year CVD risk and VAdiff based on lipids as well as BMI were significantly higher for patients compared to controls (all p<0.01). There was a strong correlation between FRSlipids and FRSBMI (r=0.97, p<0.001). Significantly higher numbers of patients than controls were smokers and obese; and reported having dyslipidaemia.
CONCLUSIONS: We found a high risk of CVD in patients with schizophrenia as compared to controls; and conclude that patients with schizophrenia need regular physical health monitoring, especially for cardiovascular risk factors.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular disease; Framingham risk score; Metabolic disorders; Schizophrenia; Vascular age

Mesh:

Year:  2016        PMID: 27796257     DOI: 10.1016/j.genhosppsych.2016.09.005

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  1 in total

1.  Cardiovascular risk in patients with severe mental illness in Italy.

Authors:  Virginio Salvi; Andrea Aguglia; Francesco Barone-Adesi; Davide Bianchi; Chiara Donfrancesco; Filippo Dragogna; Luigi Palmieri; Gianluca Serafini; Mario Amore; Claudio Mencacci
Journal:  Eur Psychiatry       Date:  2020-10-26       Impact factor: 5.361

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.